Showing results (161-170 of 431) with videos related to
Sort By:
Pageof 44
Lung Cancer (Amsterdam, Netherlands)|September 17, 2011
Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimensYoshihisa Shimada, Seiji Niho, Genichiro Ishii, et al.Clinical Lung Cancer|November 22, 2021
A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)Yoshimasa Shiraishi, Taiki Hakozaki, Shogo Nomura, et al.Cancer Science|September 5, 2022
Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010)Hirotsugu Kenmotsu, Shunichi Sugawara, Yasutaka Watanabe, et al.Journal of Thoracic Disease|June 11, 2019
Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective studyKazushi Yoshida, Shintaro Kanda, Hideaki Shiraishi, et al.Future Oncology (London, England)|January 17, 2022
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)Yusuke Okuma, Mototsugu Shimokawa, Kana Hashimoto, et al.Annals of Nuclear Medicine|August 9, 2021
18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centersKimiteru Ito, Kazuhiro Kitajima, Akira Toriihara, et al.Clinical Lung Cancer|January 10, 2017
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective AnalysisTetsuhiko Asao, Yutaka Fujiwara, Kota Itahashi, et al.Pathology International|March 8, 2013
Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lungToshihiro Shiozawa, Genichiro Ishii, Koichi Goto, et al.Clinical Lung Cancer|May 26, 2022
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic TumorYuki Shinno, Akihiko Yoshida, Ken Masuda, et al.Carcinogenesis|May 13, 2022
Genomic landscape of chemical-induced lung tumors under Nrf2 different expression levelsHironori Satoh, Yasuhito Arai, Eisaku Furukawa, et al.Pageof 44